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Abstract
Purpose Solid organ transplant (SOT) recipients are at high
risk of developing infections and malignancies. 18F-FDG
PET/CT may enable timely detection of these diseases and
help to ensure early intervention. We aimed to describe the
clinical utility of FDG PET/CT in consecutive, diagnostic un-
resolved SOT recipients transplanted from January 2004 to
May 2015.
Methods Recipients with a post-transplant FDG PET/CT per-
formed as part of diagnostic work-up were included. Detailed
chart reviews were done to extract relevant clinical information
and determine the final diagnosis related to the FDG PET/CT.
Based on á priori defined criteria and the final diagnosis,
results from each scan were classified as true or false, and
diagnostic values determined.
Results Among the 1,814 recipients in the cohort, 145 had an
FDG PET/CT performed; 122 under the indication of diag-
nostically unresolved symptoms with a suspicion of malig-
nancy or infection. The remaining (N = 23) had an FDG
PET/CT to follow-up on a known disease or to stage a known
malignancy. The 122 recipients underwent a total of 133 FDG
PET/CT scans performed for a suspected malignancy (66 %)
or an infection (34 %). Sensitivity, specificity, and positive
and negative predictive values of the FDG PET/CT in diag-
nosing these conditions were 97, 84, 87, and 96 %,
respectively.
Conclusion FDG PET/CT is an accurate diagnostic tool for
the work-up of diagnostic unresolved SOT recipients
suspected of malignancy or infection. The high sensitivity
and NPV underlines the potential usefulness of PET/CT for
excludingmalignancy or focal infections in this often complex
clinical situation.
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Introduction
Solid organ transplant (SOT) recipients have a lifetime
increased risk of developing complications related to the
transplantation. This is mainly due to the lifelong intensive
immunosuppressive therapy the patients receive during
and after transplantation, which on one hand enables the
survival of the graft, but on the other hand hampers the
host immunologic surveillance [1–3]. The most severe
consequences of the weakened immune system are severe
opportunistic infections [4] and development of malignan-
cies [5–9]. Other factors such as the chronic underlying
disease leading to the transplantation and higher rates of
co-morbidities also increase the risk of these conditions.
SOT recipients have a 3–5-fold higher risk of developing
cancers compared to the general population and the cancers
developed in this population tend to be more aggressive
with higher rates of morbidity and mortality as a conse-
quence [10].
To some extent, administration of antibiotics or chemother-
apy combined with a reduction in the immunosuppressive
treatment can cure these complications. Unfortunately, a re-
duction of the immunosuppressive therapy can lead to rejec-
tion of the graft and is a serious limitation in the management
of these patients. A close monitoring and follow-up of trans-
plant recipients is therefore crucial for timely detection and
rapid treatment of infections and malignancies [5–9, 11].
Routine microbiological, biochemical, and imaging follow-
up programmes are not always sufficient in diagnosing these
conditions, and thus more advanced diagnostic tools are
necessary.
Imaging with 18F-Fluordeoxyglucose (FDG) positron
emission tomography/computed tomography (PET/CT) can
detect metabolic changes commonly seen in malignant and
inflammatory cells and is a widely used tool in the manage-
ment of oncological patients, which has been used to localize,
stage, and evaluate treatment of a broad spectrum ofmalignant
diseases for more than a decade [12–16]. Furthermore, it is
increasingly recognized that FDG PET/CT is also valuable in
diagnosing and monitoring lymphoproliferative disorders
[17–19] and a number of non-oncologic diseases such as asep-
tic inflammation and infection [20–26].
FDG PET/CT may thus be a helpful tool in the manage-
ment of SOT recipients. Conversely, the available literature of
the role of FDG PET/CT in transplant recipients is limited and
based on few cases or specific clinical issues.
Therefore, we initiated a retrospective review of FDG PET/
CT after SOT to examine the diagnostic values of FDG PET/
CT in detecting and diagnosing infections and cancer among
diagnostic unresolved SOT.
Materials and Methods
Study design and participants
In this retrospective cohort study we enrolled all children and
adults consecutively transplanted with a heart, lung, liver, or
kidney at the Copenhagen University Hospital, Rigshospitalet
between January 2004 and May 2015. All patients in this
period are registered and followed in an ongoing database:
the Management of Post-Transplant Infections in
Collaborating Hospitals (MATCH) programme [27]. This in-
cludes all liver and lung transplantations in Denmark in that
period and all kidney and heart transplantations in the eastern
region of Denmark. Eligible recipients were those with an
FDG PET/CT performed in the course after transplantation
under the indication of suspected infection or malignancy
not revealed by routine microbiological, biochemical, or im-
aging tests.
Recipients where FDG PET/CT was performed to follow-
up on an already diagnosed disease were excluded, e.g. sur-
veillance after coincidental finding of a cholangiocarcinoma
from the removed liver in a liver transplant recipient, staging
of a known lung cancer or follow-up after treatment of an
abscess. All referrals were reviewed manually. Patient flow
is described in Fig. 1.
The research is conducted after approval of the National
Data Protection Agency (2012-58-0004, RH-2015-67, with I-
Suite number: 03787) and the Regional Ethics committee
(H-2-2014-050).
FDG PET/CT imaging
All patients were scanned on an integrated FDG PET/CT
scanner Biograph TruePoint (16-, 40-, or 64-slice), Siemens
Medical Solution, Malvern PA; Biograph 64 mCT, Siemens
Medical Solutions, Malvern PA or Discovery LS, 4 Slice,
General Electric, Milwaukee, WI, USA). The patients were
instructed to fast for at least 6 h before intravenous
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administration of FDG. A dosage of 200–555 MBq FDG
(4 MBq/kg) was injected and the scanning was performed
after 60-min rest. Awhole body FDG PET/CTwas performed
(skull base to proximal thigh). The diagnostic CT scans were
acquired at 120–140 keV with iodine based intravenous con-
trast agent unless contraindicated. A multi-bed PETscan, with
a scan time of 2–3 min per bed position depending on scanner
type and patient BMI, was performed after the CT. CT data
were used for attenuation correction. The attenuation
corrected PET data were reconstructed iteratively using a 3
D ordered-subset expectation-maximization algorithm
(OSEM), for scans performed on the Biograph mCT this in-
cluded point spread function and time of flight information.
For clinical use, all fused PET/CT scans were reviewed by a
nuclear medicine physician and a radiologist.
Follow-up and classification
As part of the study, a detailed chart review was done to
confirm disease status and extract additional important clinical
details, including lab tests, microbiology, imaging, and pathol-
ogy, for a period from the first PET/CT scan until death or
censoring (minimum 12 months follow-up).
Based on an evaluation of all available data the final clin-
ical diagnosis was determined. Furthermore, in order to eval-
uate the full spectrum of diagnostic examinations performed
prior to the FDG PET/CT, all laboratory data, imaging, biop-
sies, and culture specimens in the 30 days prior to FDG PET/
CTwere registered.
A nuclear medicine specialist reviewed the PET/CT reports
(blinded to other examinations and clinical follow-up) and
classified each scan as normal, suggestive of infection or ma-
lignancy, inconclusive, and/or other clinical relevant findings.
Furthermore Maximum Standardized Uptake Value normal-
ized to body weight (SUVmax) was registered retrospectively
for all lesions described as positive in the PET/CT report
(max. five lesions per patient). The results of the FDG PET/
CT reports were compared with the final clinical diagnosis by
two independent physicians and based on á priori defined
classification (see Table 1) each case was then classified as
true positive, contributory to diagnosis; true negative, contrib-
utory to exclusion; false positive, non-contributory; or false
negative, non-contributory.
In cases of disagreement an arbitration process among the
two reviewers was initiated in order to achieve agreement. In
cases with insufficient clinical information and where no cer-
tain diagnosis was made, a suggested classification based on
the available information was made for the purpose of sensi-
tivity analyses.
Statistics
Statistical analyses were performed using Statistical Package
for the Social Sciences (SPSS) version 22 (IBM, New York,
NY, USA). Differences in subgroups were calculated using the
Pearson’s Chi-squared test. Sensitivity was defined as: [num-
ber of true positive cases]/[total number of true positive and
false negative cases]. Specificity was defined as: [number of
true negative cases]/[total number of false positive and true
negative cases]. Positive predictive value (PPV) was defined
as: [number of true positive cases]/[total number of true posi-
tive and false positive cases]. Negative predictive value (NPV)
Abbreviations: FDG,18 F-Fluordeoxyglukose; PET/CT, positron emission tomography/computed tomography.
Recipients with FDG PET/CT 
performed for suspected 
infection or malignancy 
N=122 
Recipients with solid organ 
transplantation 
N=1814 
Excluded, N=23
FDG PET/CT performed to 
stage a malignancy or to 
follow-up on a known disease 
Recipients with FDG PET/CT 
performed after transplantation 
N=145 
Lost to follow-up, N=2 
Fig. 1 Flow chart of solid organ
transplant recipients with a
subsequent FDG PET/CT scan;
FDG PET/CT performed in
diagnostic unresolved recipients
suspected of infection or
malignancy was included in the
study
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was defined as: [number of true negative cases]/[total number
of true negative and false negative cases]. Exact 95 % confi-
dence intervals (CI) based on the binomial distribution were
calculated for each of these. Cases with no certain diagnosis
andwhere a classification in true or false was not possible were
excluded from the analysis initially. A suggested classification
was subsequently included in a sensitivity analysis.
Results
Patient characteristics
Among the 1814 SOT recipients in the cohort with a median
follow-up of 33 months [interquartile range (IQR) 10–69],
145 (8 %) recipients had a total of 219 FDG PET/CT scans
performed.
Of those, 122 (84 %) recipients were diagnostically unre-
solved at time of FDG PET/CT and had a total of 133 FDG
PET/CT scans performed under this indication. Twenty-three
recipients had a total of 86 FDG PET/CT scans performed for
staging and follow-up of known infectious or malignant dis-
ease and were excluded from this study, see Fig. 1.
The median time from transplantation to the first FDG
PET/CT scan was 19 (IQR 4–49) months. Eleven recipients
had a second FDG PET/CT performed a median of 11 (IQR
5–44) months after the first one, due to a new clinical situation
without relation to the clinical situation leading to the first
FDG PET/CT scan.
Patient characteristics for patients with and without a post-
transplant FDG PET/CT scan performed for diagnostic pur-
poses are listed in Table 2. There was no difference between
the two groups in terms of gender, age, and time period of
transplantation. The proportion of liver and lung transplants
was larger among those with a FDG PET/CT compared to
those without (38 % vs. 25 % and 26 % vs. 18 % p = 0.002,
respectively), whereas the proportion of kidney transplants
was smaller (33 % vs. 48 %, p = 0.002).
The first FDG PET/CT scan was performed due to
suspected malignancy in 80/122 or infection in 42/122 re-
cipients, whereas the 11 recipients with a second FDG
PET/CT had this performed due to suspected malignancy
in 8/11 or infection in 3/11. At time of the FDG PET/CT
(N = 133), the recipients presented with fever of unknown
origin (FUO) in 38 of 133, organ specific symptoms such
as diarrhoea, stomach pain, coughing, and neurologic
symptoms in 39 of 133, one or more B-symptoms in 25
of 133, and altered biochemical or microbial markers such
as sustained elevated CRP, LDH, ALT, or Epstein-Barr vi-
rus (EBV) polymerase chain reaction (PCR) in 30 of 133.
In one recipient, the FDG PET/CT was performed due to
coincidental finding of pathologic appearing lymph nodes
of the liver hilum on a CT scan. The patients were exam-
ined with other diagnostic procedures within 30 days from
FDG PET/CT in 132/133 (99 %) of the cases. This includ-
ed laboratory analysis in 118/133 (89 %), culture samples
in 101/133 (76 %), other imaging in 96/133 (72 %), or
biopsies in 54/133 (41 %), respectively. See Online
Resource 1 for further details on type and frequency of
Table 1 Classification of each scan according to the clinical presentation, the clinical FDG PET/CT reports, other available examinations, and
treatment response
Classification Conclusion of the FDG
PET/CT
Histology or cytology
examination of the abnormality
found on the PET/CT or a
positive/negative culture
If no histology is available, then all of the following
criteria must be in accordance with the PET/CT
True positive,
contributory to
diagnosis
Abnormality suggestive
of infection or
malignancy found
Agree with the PET/CT a) relevant symptoms
b) relevant treatment applied and response seen
c) no other findings contradicting the results of the
PET/CT scan within 3 months
True negative,
contributory to
exclusion
No abnormality found Agree with the PET/CT a) no further symptoms indicating disease developed
b) recovery of symptoms without treatment
c) no further findings indicating disease within 3
months
False positive,
non-contributory
Abnormality suggestive
of infection or
malignancy found
Disagree with the PET/CT a) no further symptoms indicating disease developed
b) recovery of symptoms without treatment
c) no further findings indicating disease within 3
months
False negative,
non-contributory
No abnormality found Disagree with the PET/CT a) relevant symptoms
b) relevant treatment applied and response seen
c) further findings contradicting the result of the
PET/CT scan within 3 months
Abbreviations: FDG, 18 F-Fluordeoxyglucose; PET/CT, positron emission tomography/computed tomography
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diagnostic analysis prior to FDG PET/CT. One case
suspected for occult cancer due to weight loss and loss of
appetite over a period of a few months, only blood samples
were taken 43 days prior to the FDG PET/CT.
The final clinical diagnosis in relation to the FDG PET/CT
(N = 133)
The complete diagnostic work-up lead to no pathology in 41
of 133 (31 %), a cancer diagnosis in 32 of 133 (24 %) [includ-
ing post-transplant lymphoproliferative disorders (PTLD)
(N = 12, Fig. 2), lung cancer (N = 7), liver cancer (N = 3),
metastasis with unknown primary tumour (N = 2), acute my-
eloid leukaemia (AML) (N = 1), angiosarcoma (N = 1), blad-
der cancer (N = 1), cervical cancer (N = 1), gall bladder cancer
(N = 1), renal cancer (N = 1), prostate cancer (N = 1), non-
melanoma skin cancer (N = 1)], an infection diagnosis in 32
of 133 (24 %) (including 24 focal and eight disseminated
infections), and other specific findings of potential clinical
relevance in 18 of 133 (14 %), such as rejection of the liver
or lung graft or unspecific inflammation of a lymph node.
In ten cases (7 %) determination of a final diagnosis was
not possible, as the patients were lost to follow up (N = 2) or
due to lack of sufficient clinical and diagnostic information
(N = 8). The latter are described in details in Table 3.
Classification and diagnostic values of the FDG PET/CT
scans (N = 133)
The FDG PET/CT suggested a malignancy in 32 (24 %) and
an infection in 32 of 133 (24 %), whereas PET/CTwere with-
out any suspicion of infection or malignancy in 59 of 133
(44 %) cases. Furthermore, eight patients remained undiag-
nosed and two were lost to follow-up (8 %).
Classification of the scans as true or false was made in
initial agreement by two reviewers in 118 of 133 scans. The
remaining 15 were agreed on after an arbitration process.
The scans were classified as true positive in 66 (54 %), true
negative in 46 (37 %), false positive in 10 (8 %), and false
negative in one (1 %). Sixty-five (53 %) of the scans were
confirmed by either microbiology, histology, or cytology ex-
amination, whereas the classification was based on patient
history and other clinical findings in 58 (47 %), Table 4.
In eight cases where no diagnosis could be made initially
due to insufficient clinical information, a suggested classifica-
tion was made for the purpose of sensitivity analysis, Table 3.
The two recipients whowere lost to follow-upwere exclud-
ed from the analysis.
Among the 66 true positive scans, the diagnostic work-up
lead to a cancer diagnosis in 19 (29 %), an infection in 28
(42 %), PTLD in 12 (18 %), and other specific findings in
seven (11 %) cases.
Table 2 Patient Characteristics
of recipients with and without a
post-transplant FDG PET/CT
scan performed for suspected
infection or malignancy
Patient characteristics All recipients Recipients with
a PET/CT
N (%)
Recipients with
no PET/CT
N (%)
p
Total 1814 122 (7) 1692 (93) -
Gender 0.6
Males 1063 (59) 69 (57) 994 (58)
Females 751 (41) 53 (43) 698 (42)
Age at transplantation 0.5
Median,( IQR) 48 (35–57) 49 (34–59) 48 (35–57)
Type of transplantation 0.002
Kidney 846 (47) 40 (33) 806 (48)
Liver 493 (27) 46 (38) 447 (26)
Lung 333 (18) 31 (25) 302 (18)
Heart 142 (9) 5 (4) 137 (8)
Year of transplantation 0.8
≤2006 403 (22) 25 (21) 378 (22)
2007-2009 441 (24) 31 (25) 410 (24)
2010-2011 374 (21) 29 (24) 345 (20)
>2011 596 (33) 37 (30) 559 (33)
Number of PET/CT scans performed -
1 111 (91) 111 (91) 0 (0)
2 11 (9) 11 (9) 0 (0)
Abbreviations: FDG 18 F-Fluordeoxyglucose, PET/CT positron emission tomography/computed tomography,
IQR interquartile range, N number
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In eight of ten false positive scans the FDG PET/CT scan
suggested malignancy, but this was disproved by histology
examination of the malignant appearing area and no malig-
nancy was ever diagnosed during the follow-up period. One
FDG PET/CT scan suggested malignancy in the mediastinum
and the liver hilum, but histology examinations of both areas
rejected malignancy, but suggested rejection of the liver graft
and sarcoidosis of the mediastinal lymph nodes. The last false
positive scan suggested malignancy in the lungs and the thy-
roid gland, but fungal infection was detected in bronchoalve-
olar lavage fluid.
One scan was classified as false negative and was without
any focal findings; however, the patient was diagnosed with
recurrence of a non-melanoma skin cancer of the cheek, with
metastases to the ear, facial nerve and parotid gland within one
month from the FDG PET/CT was performed.
The diagnostic values of FDGPET/CTare listed in Table 5.
Sensitivity analysis including the eight initially unclassifi-
able scans from Table 3, resulted in sensitivity, specificity,
positive predictive and negative predictive values of 97, 84,
87, and 96 %, respectively.
Median SUVmax of findings on FDG PET/CT (N =
164) were lower in cases where follow-up revealed no ab-
normality compared with those with clinically significant
findings (p = 0.03). Comparing PET-positive findings later
confirmed as, respectively, malignancy and infection, me-
dian SUVmax was lower in the latter, albeit not significant-
ly (p = 0.2), Fig. 3.
Discussion
This paper presented the diagnostic accuracy of an FDG
PET/CT in a large group of SOT recipients with unresolved
clinical issues, suspected for a malignancy or an infection.
The patients had been examined extensively with other
imaging modalities, culture specimens, and other laborato-
ry tests prior to FDG PET/CT without this leading to a
diagnosis; however, after an FDG PET/CT scan was per-
formed, cancer or severe infection could correctly be iden-
tified or ruled out in the vast majority of the cases (112/123
FDG PET/CT scans) with positive and negative predictive
values of 87 and 98 %, respectively. Only in eight cases the
recipients remained diagnostic unresolved, even after FDG
PET/CT was performed (Table 3). In most of these cases,
the symptoms resolved over time in the following couple
of months, either spontaneously or on empiric antibiotic
treatment, and none were diagnosed with a malignancy or
severe focal infection. Our results thus indicate that FDG
PET/CT can safely and accurately exclude focal disease in
SOT recipients experiencing unexplained symptoms
pointing towards malignant or infectious disease. There
was a clear tendency towards higher SUVmax of lesions
in cases with a clinically significant finding compared to
patients without disease (p = 0.03), albeit non-significant
when comparing lesions in cases with an infection vs. can-
cer (p = 0.2). The latter is a well-known drawback of the
FDG-PET technology.
Historically, FDG PET/CT has been hampered by a high
frequency of false positive findings [23, 28–32], potentially
leading to an increasing number of futile invasive tests. In this
setting, we found a total of nine false positive malignancies
and one false positive infection. In all cases further examina-
tions were made with biopsies and two were diagnosed with
an infection and rejection of the graft, respectively. Since the
FDG PET/CT could also contribute to the diagnosis of these
Fig. 2 A three year old kidney and liver recipient with fever and elevated
EBV DNA in plasma 3 months after transplantation, suspected for post-
transplant lymphoproliferative disorders (PTLD). A) The FDG PET/CT
showed increased FDG uptake in enlarged and normal sized lymph nodes
above and below diaphragm including the extremities, in the
rhinopharynx, tonsils, and spleen compatible with post-transplant lym-
phoproliferative disorders. B) Complete metabolic and structural remis-
sion after 3 weeks of rituximab treatment. The area with increased FDG-
retention in the right fossa corresponds to urine excretion in the well-
functioning graft
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two it can be debated whether they were in fact false positive.
The remaining eight were not diagnosed with any disease in
relation to the FDG PET/CT. This relatively low false-positive
rate was found despite the application of a rather strict true
positive criteria; only FDG PET/CT scans correctly finding
and describing changes as either malignancy or infection were
Table 3 Diagnostic unresolved recipients where classification of the FDG PET/CT scan as true or false was not possible due to lack of sufficient
clinical and diagnostic information, and a suggested classification for the sensitivity analysis
Cases Type of
transplant
Symptoms/clinical
findings
Suspected
condition
FDG PET/CT finding Conclusion Suggested
classification
1 Liver Fatigue
Hyperbilirubinemia
Lymphopenia
PTLD Inflammation of the
lung and porta
hepatica
No explanation for the symptoms was
found. Infection, lymphoma and
rejection of the graft were ruled out.
True negative
2 Liver Nightly sweating Malignancy Inflammation or
infection of lungs,
tonsils, and lymph
node on neck
Histology examination of lymph node
on neck was normal. No further
explanation for the symptoms was
found. Improved spontaneously
without treatment.
False positive
3 Kidney Fever, consistent elevated
CRP despite empiric
antibiotic treatment
(FUO)
Focal infection or
malignancy
Activated bone
marrow
Inflammation of small
intestine
No infections were detected. The
patient improved on empiric
antibiotic treatment.
True negative
4 Kidney Haemolytic anaemia Malignancy No abnormality Complicated patient with possible, but
non-confirmable myelodysplastic
syndrome. Developed endocarditis
and sepsis and died from his com-
plications three months after the
PET/CT scan was performed. No
certain diagnosis was made.
False negative
5 Kidney Unexplained elevated CRP
Normal leukocytes
Infection No abnormality Known HIV infected patient. No
explanation for the elevated CRP
was found.
True negative
6 Kidney Fever and malaise
Elevated CRP and ESRD
(FUO)
Infection or
malignancy
Inflammation of the
lung
No infection was detected. Presumed
infection. Improved on continued
treatment with empiric antibiotics
True positive
7 Kidney Vomiting and fever
(FUO)
Infection No abnormality No infections were detected. Improved
on continued empiric antibiotic
treatment
True negative
8 Lung Daily fever independent of
empiric antibiotic
treatment (FUO)
Infection No abnormality was
found
No infections were detected. Improved
on continued empiric antibiotic
treatment
True negative
Abbreviations: FDG 18 F-Fluordeoxyglucose, PET/CT positron emission tomography/computed tomography, PTLD post-transplant lymphoprolifera-
tive disorders, FUO fever of unknown origin, HIV human immunodeficiency virus, ESRD end-stage renal disease
Table 4 Classification of FDG
PET/CT scans performed in
diagnostic unresolved cases
suspected of infection or
malignancy (N = 123) according
to histology examination or
clinical history
Classification Confirmed by histology or
cytology examination or a
positive/negative culture
N (%)
Classification based on
patient history, symptoms,
treatment, and other findings1
N (%)
Total
N (%)
True positive, contributory to
diagnosis
42 (63) 24 (37) 66 (54)
True negative, contributory to
exclusion
12 (26) 34 (74) 46 (37)
False positive, non-contributory 10 (100) 0 (0) 10 (8)
False negative, non-contributory 1 (100) 0 (0) 1 (1)
Total 65 (53) 58 (47) 123
(100)
Abbreviations: FDG 18 F-Fluordeoxyglucose, PET/CT positron emission tomography/computed tomography, N
Number
1. Other findings include findings on other imaging, clinical signs, and treatment response or the absence of all
three
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classified as true positive. The relatively low number of false
positive scans in our study (8 %), compared to previous stud-
ies, may likely reflect the á priori high risk of malignancy and
infection in this group of patients; in 48 % of the 133 cases
either a diagnose of malignancy or infection was confirmed
after FDG PET/CT. In other words, unexplained sustained
symptoms among SOT recipients, relatively often are an ex-
pression of a malignancy or an infection. Furthermore, fever
of unknown origin (FUO), which more than one third of the
recipients presented with at time of FDG PET/CT has been
associated with cancer in up to 30 % of the cases.
FUO usually carries significant diagnostic challenges
where no diagnosis can be made in up to 50 % of the patients
[24, 33]. FDG PET/CT has been shown to be clinically useful
in up to 70 % of these cases with high negative predictive
value of up to 100 % [24, 33–36]. The present study con-
firmed that this also applies for SOT recipients since very
few recipients remained diagnostic unresolved after FDG
PET/CT was performed.
Only one scan was classified as false negative resulting in a
very high negative predictive value.
The false negative scan was found in a recipient with re-
currence of a non-melanoma skin cancer of the cheek with
spread to the facial nerve and parotid gland. The challenges
in discriminating the imaging artefacts related to physiological
FDG uptake from those related to malignant uptake is a well-
recognized diagnostic dilemma [37], in particular in salivary
glands and the nervous system, and may be an explanation for
overlooking this cancer case. The high negative predictive
value presented here is in accordance with what has been
demonstrated in previous studies [21, 24, 26, 38].
The use of FDG PET/CT in the detection andmonitoring of
graft rejection has been suggested in recent animal based stud-
ies [39–42]. None of the scans in the present study were
Table 5 Diagnostic values of the
123 FDG PET/CT scans in 122
diagnostic unresolved recipients
(123 scans) suspected of infection
or malignancy according to
diagnosis after complete
diagnostic work-up
All scans
(N = 64)
Infection1
(N = 32)
Malignancy2
(N = 32)
Diagnostic values % 95 % CI % 95 % CI3 % 95 % CI3
Sensitivity 99 (92–100) 100 (87 – 100) 97 (86 – 100)
Specificity 82 (70–91) - -
Positive predictive value 87 (77–94) 96 (82 – 100) 100 (91 – 100)
Negative predictive value 98 (89–100) - -
Abbreviations: FDG 18 F-Fluordeoxyglucose, PET/CT positron emission tomography/computed tomography, CI
confidence intervals.
1. Diagnostic values of recipients diagnosed with an infection after complete diagnostic work-up.
2. Diagnostic values of recipients diagnosed with a malignancy after complete diagnostic work-up.
3. Specificity and negative predictive values could not be calculated due to few scans in these categories.
*p=0.001
*p=0.02
p=0.2
p=0.8
p=0.6
Fig 3 Median maximum
standardized uptake values of
lesions found on FDG PET/CT
(lesion-based analysis, N = 164)
according to the final diagnosis
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performed for suspected graft rejection and none suggested
graft rejection. However, two scans found an abnormal FDG
uptake of the graft that was later confirmed to be rejection of
the kidney and lung graft, respectively. Three additional recip-
ients were diagnosed with a graft rejection of the lung (N = 1)
and liver (N = 2); although these were not detected by the FDG
PET/CT scan. The few numbers in this study and the absence
of evidence in support of PET/CT in graft rejection stresses the
fact that interpretation should be made with caution.
Studies on the clinical value of an FDG PET/CT in
suspected infection and inflammation are limited, and it is still
debated whether FDG PET/CT actually contributes to the di-
agnosis or if the diagnosis would have beenmade independent
of the FDG PET/CT. However, with increasing amount of
evidence, FDG PET/CT is now recommended in the manage-
ment of a number of infectious diseases including osteomye-
litis, suspected spinal infection, and evaluation of patients
with bacteremia [26]. Also, previous studies have demonstrat-
ed that early FDG PET/CT in patients suspected for a
bacteraemia can ensure timely diagnosis, minimize the admis-
sion time of the patients, and improve survival [25, 43].
In the present study, one third of the recipients were diag-
nosed with a variety of mainly focal infections, and in all but
one case, the FDG PET/CT was able to correctly detect the
infection. In the one case, the FDG PET/CT suggested malig-
nancy in the lung and thyroid gland, but further examinations
revealed fungal infection of the lung. Other cases of fungal
infection, for instance, of the lung and liver, were, however,
correctly detected by the FDG PET/CT. Thus, FDG PET/CT
is likely of clinical value in most cases with focal infections.
Dual time-point (DTP) imaging has been suggested to be
able to distinguish malignancies from infection or inflamma-
tion and may thus have a potential to help guide clinicians in
planning the appropriate intervention. The main rationale be-
ing different metabolic rates between malignant and benign
cells resulting in different retention index, thus enabling dis-
crimination between increased FDG-uptake on a malignant
respectively inflammatory basis [44]. However, more recent
studies and meta-analysis have failed to prove a significant
clinical benefit of DTP imaging [45–47]. Because of the ret-
rospective nature of our study, it was not possible to assess
DTP imaging in SOT patients.
Since FDG may give false positive results due to its unspe-
cific nature towards malignant and inflammatory cells, new
imaging tracers specifically targeted towards inflammatory
cells are being investigated intensively. PET imaging using
tracers such as translocator protein, formyl peptide receptor,
and COX inhibitors has showed promising results in regards
of detecting neuroinflammation, arteriosclerosis and in in-
flamed lungs [48]. Further investigations are, however, re-
quired before these can be introduced in the clinical setting.
The present study is limited by the fact that it is a retrospec-
tive and non-controlled study. We cannot exclude that some
patients may have been diagnosed and treated successfully
independent of the FDG PET/CT. Neither can we conclude
that the FDG PET/CT is in fact better than other diagnostic
procedures since we have no control group. However, the
general indication for an FDG PET/CT in this cohort was
suspicion of an infection or malignancy not revealed by stan-
dard diagnostic procedures, and thus most patients had under-
gone an exhausting diagnostic algorithm prior to the FDG
PET/CT. Furthermore, the indications for an FDG PET/CT
were unchanged during the entire cohort period and among
the different departments.
Since very few studies have examined the role of an FDG
PET/CT among transplant recipients a retrospective design
was chosen to elucidate this subject. Further studies of pro-
spective nature are recommended to confirm our findings. We
have tried to minimize the potential selection bias by includ-
ing a large cohort of all SOT, transplanted consecutively at a
national transplant centre and included in an ongoing data-
base, i.e. the MATCH programme. The cohort is thus likely
to represent a non-selected group of patients. We only includ-
ed recipients with unresolved clinical issues prior to FDG
PET/CT, which is likely to represent a more diagnostic chal-
lenging group of patients and furthermore, the included and
excluded recipients were comparable in regards of demo-
graphics and calendar period of transplantation.
To our knowledge this is the first study to describe the
diagnostic role of FDG PET/CT in non-selected diagnostic
unresolved SOT recipients. We have demonstrated that the
use of FDG PET/CT in the follow-up of SOT recipients with
non-specific and unexplained symptoms at our hospital has
high diagnostic values and can reliably detect or exclude ma-
lignancies or infections.
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